News

Cardio3 starts Phase III
Enlarge image

Clinical trialsBelgiumEU

Cardio3 starts Phase III

23.11.2012 - Belgian Cardio3 BioSciences has received authorisation to begin a European Phase III trial for its autologous stem cell therapy for heart failure.

The Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) Phase III trial will recruit at least 240 patients with chronic advanced symptomatic heart failure, announced the Wallonia-based company on 22 November. The prospective, double-blinded study will compare a treatment with Cardio3’s lead product C3BS-CQR-1 to a sham treatment. The primary endpoint of the trial is a composite endpoint including mortality, morbidity, quality of life, Six Minute Walk Test and left ventricular structure and function at 9 months post-procedure. 

“We believe C3BS-CQR-1 has the potential to become an alternative to heart transplantat, which is the only curative treatment for heart failure available today“, stated Christian Homsy, CEO of Cardio3 BioSciences adding that – to his knowledge –  this would be the first Phase III trial ever for a regenerative therapy with this indication. "We look forward to confirming the promising results we have already seen in our Phase II study,” concluded Homsy. Cardio3 tested its treatment in Phase II between 2009 and 2010 in multiple clinical sites in Belgium, Serbia and Switzerland.

The therapy involves taking stem cells from a patient’s own bone marrow and re-programming those cells so that they go on to become heart cells. The cardiopoietic cells, are then injected back into the patient’s heart through a minimally invasive procedure using a catheter with the aim of repairing damaged tissue and improving heart function and patient clinical outcomes.

© eurobiotechnews.eu/bk

http://www.european-biotechnology-news.com/news/news/2012-04/cardio3-starts-phase-iii.html

FinancingDenmark

18.10.2014 After raising US$220.5m (€172m) with its IPO, fast Forward Pharma’s lucky streak hits an obstacle on the road to success with shares falling 17% on its first day of trading.

M&AUKItaly

17.10.2014 One of the biggest pharma mergers of the year has been called off. Abbvie has dropped plans to acquire UK’s Shire following new US tax rules.

FinancingUKBelgium

15.10.2014 Bicycle Therapeutics wins €25m backing by major pharma venture capitalists for the development of a new class of oncology drugs.

FinancingGermanySwitzerlandNetherlands

13.10.2014 Biotechnology IPOs are back in fashion – German Probiodrug AG wants to raise €32m with its IPO, whilst Swiss Molecular Partners AG hopes the launch of its IPO will gain a revenue of €145m.

BusinessIreland

10.10.2014 Actavis has announced plans to merge with American pharma company Durata - a move that will strengthen their infectious diseases portfolio.

RegulationEU

07.10.2014 In an unprecedented move, the European Medicines Agency has approved a system allowing the future analysis of clinical trial data.

FinanceNetherlandsEU

06.10.2014 Another fund from the Netherlands has raised €92m in its first close and will invest the money in companies developing innovative therapeutics, medical devices and diagnostics.

FinanceNetherlandsUKSwitzerland

03.10.2014 Dutch venture capitalist LSP has achieved its monetary milestone by raising €80m for its fifth fund - with a goal of €150m.

PoliticsEULithuaniaPoland

02.10.2014 New EU commission chief Jean-Claude Juncker is on the defensive after members of Parliament and NGOs criticised his reorganisation of the health technology units.

EbolaEUFrance

30.09.2014 In the face of the Ebola outbreak sweeping the West African countries, the EMA has started to review investigational treatments for the deadly virus disease.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MOLOGEN6.46 EUR16.82%
  • CYTOS0.17 CHF13.33%
  • WILEX2.25 EUR7.14%

FLOP

  • 4SC0.87 EUR-1.14%
  • CYTOTOOLS31.45 EUR-0.47%
  • ADDEX3.20 CHF0.00%

TOP

  • BIOFRONTERA2.88 EUR30.9%
  • ADDEX3.20 CHF3.2%
  • HBM84.00 CHF0.6%

FLOP

  • CYTOS0.17 CHF-29.2%
  • PAION2.22 EUR-27.2%
  • 4SC0.87 EUR-25.6%

TOP

  • SANTHERA82.40 CHF2085.7%
  • CO.DON2.58 EUR163.3%
  • PAION2.22 EUR146.7%

FLOP

  • CYTOS0.17 CHF-95.7%
  • 4SC0.87 EUR-50.8%
  • THERAMETRICS0.07 CHF-50.0%

No liability assumed, Date: 20.10.2014